Un-Audited Financial Results of the Company for the Third Quarter and Nine months ended December 31, 2025, along with Auditors' Limited Reports, in accordance with the provisions of Regulation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors approved the unaudited financial results for Q3 FY26 (ended Dec 31, 2025) and the nine-month period FY26. Revenue from operations was NIL for Q3 FY26, with the company reporting a net loss of ₹1.15 lakhs against a profit of ₹1.13 lakhs in Q2 FY26. For the nine months ended Dec 2025, the net loss stood at ₹1.82 lakhs versus a loss of ₹1.34 lakhs in the corresponding period last year. Total expenses for the quarter were ₹1.15 lakhs, mainly comprising depreciation (₹0.73 lakhs) and employee costs (₹0.39 lakhs). EPS for the quarter was negative at ₹0.02. The filing also reflects the company's transformation, evident from its rebranding from Bansisons Tea Industries to Novyra Pharmachem, suggesting a strategic pivot into the pharmaceutical/chem trading business. The statutory auditors issued a clean limited review report with no qualifications.
Retail investors should note that operational revenue remains zero, indicating the company is still in a transition phase with no active business income; while quarterly losses are small in absolute terms, the lack of revenue generation and persistent losses raise concerns about near-term business sustainability until the new pharma identity starts contributing meaningfully.